Open Access<p>Insights into the Management of Overactive Bladder with Transdermal Oxybutynin: A Practical Review</p>
Author(s) -
Raúl Vozmediano-Chicharro,
Pedro Blasco Hernández,
Blanca Madurga-Patuel
Publication year - 2020
Publication title -
research and reports in urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.506
H-Index - 20
ISSN - 2253-2447
DOI - 10.2147/rru.s266400
Subject(s) - oxybutynin , medicine , overactive bladder , anticholinergic , adverse effect , intensive care medicine , anticholinergic agents , transdermal , nocturia , quality of life (healthcare) , urinary incontinence , urology , urinary system , pharmacology , alternative medicine , nursing , pathology
Overactive bladder (OAB), clinically defined as urinary urgency, with or without incontinence, generally accompanied by an increase in urinary frequency and nocturia, after any local disease or metabolic disorder that would explain these symptoms have been ruled out, is a highly prevalent condition that affects millions of men and women worldwide. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals' lives, representing a particularly impactful health burden to quality of life and productivity. Besides a wide range of conservative treatments, the clinical efficacy of which remains an open issue, antimuscarinics are the mainstay of pharmacotherapy for this condition but anticholinergic troublesome side effects like dry mouth, and the patient's perception of lack of efficacy and poor adherence, are common reasons of abandonment of treatment. An alternative to oral administration treatment, with a lower incidence of dry mouth and other anticholinergic adverse effects, might be attractive to patients and a real treatment option for physicians. Delivery of oxybutynin directly through the skin with oxybutynin transdermal (OXY-TDS) avoids the first-pass hepatic metabolism that occurs with orally administered oxybutynin and prevents the appearance of anticholinergic adverse events. OXY-TDS being equally effective than oral treatment improves adherence, persistence, and patient satisfaction. The aim of this review is to focus on evidence available of the use of OXY-TDS in the management of patients with OAB, and to help clinicians in the challenges involved in the treatment options for patients with this condition.